A.D.A.
A.D.A. – Advanced Drug Administration is an innovative startup dedicated to developing advanced inhalation therapies for interstitial lung diseases, leveraging nanomedicine-based technology to provide targeted, effective, and patient-centric treatments. Their mission focuses on addressing the urgent need for better therapies for rare lung diseases through innovative drug delivery platforms that maximize efficacy and minimize toxicity.
Industries
Nr. of Employees
small (1-50)
Patents
Large weight scale for detecting possibility of bedsore, and bedsore detecting method
US-12613124-B2
View DetailsMoisture meter, state diagnosis method for moisture meter, and storage medium
US-12366511-B2
View Details
Large weight scale for detecting possibility of bedsore, and bedsore detecting method
US-12613124-B2
View DetailsMoisture meter, state diagnosis method for moisture meter, and storage medium
US-12366511-B2
View DetailsProducts
Inhaled TGF‑β inhibitor formulation (antifibrotic carrier)
An inhaled formulation embedding a TGF‑β pathway inhibitor into an amphiphilic nanoparticle carrier that also exerts intrinsic antifibrotic effects; designed for local pulmonary administration to modulate fibrotic signalling.
Mycophenolic‑acid‑derived self‑assembling nanoparticle immunomodulator
A self‑assembling nanoparticle system composed of a mycophenolic acid prodrug designed for inhalation to selectively inhibit lymphocyte proliferation and modulate pulmonary immune activity; formulation increases aqueous solubility and mucus penetration compared with traditional MPA formulations.
Combination nanoparticle therapy (antifibrotic + immunomodulator)
A combination approach where an antifibrotic small molecule is encapsulated into the self‑assembling immunomodulatory nanoparticles to address both fibrotic mechanisms and immune hyperactivation in the lung.
Drug AND Delivery
An innovative inhalation nanomedicine technology platform utilizing nanoparticles composed entirely of the therapeutic agent itself, achieving 100% drug loading without inactive carriers.
ADA001
ADA001 is an antifibrotic formulation targeting the TGF-β pathway, indicated for idiopathic pulmonary fibrosis (IPF) to slow disease progression and preserve lung function.
ADA002
ADA002 is a self-assembling, immunosuppressant-based nanoparticle therapy targeting autoimmune-driven interstitial lung diseases, particularly connective tissue disease-associated ILDs (CTD-ILDs).
Inhaled TGF‑β inhibitor formulation (antifibrotic carrier)
An inhaled formulation embedding a TGF‑β pathway inhibitor into an amphiphilic nanoparticle carrier that also exerts intrinsic antifibrotic effects; designed for local pulmonary administration to modulate fibrotic signalling.
Mycophenolic‑acid‑derived self‑assembling nanoparticle immunomodulator
A self‑assembling nanoparticle system composed of a mycophenolic acid prodrug designed for inhalation to selectively inhibit lymphocyte proliferation and modulate pulmonary immune activity; formulation increases aqueous solubility and mucus penetration compared with traditional MPA formulations.
Combination nanoparticle therapy (antifibrotic + immunomodulator)
A combination approach where an antifibrotic small molecule is encapsulated into the self‑assembling immunomodulatory nanoparticles to address both fibrotic mechanisms and immune hyperactivation in the lung.
Drug AND Delivery
An innovative inhalation nanomedicine technology platform utilizing nanoparticles composed entirely of the therapeutic agent itself, achieving 100% drug loading without inactive carriers.
ADA001
ADA001 is an antifibrotic formulation targeting the TGF-β pathway, indicated for idiopathic pulmonary fibrosis (IPF) to slow disease progression and preserve lung function.
ADA002
ADA002 is a self-assembling, immunosuppressant-based nanoparticle therapy targeting autoimmune-driven interstitial lung diseases, particularly connective tissue disease-associated ILDs (CTD-ILDs).
Expertise Areas
- Inhaled nanomedicine development
- Interstitial lung disease therapeutics (IPF, CTD‑ILD, SSc‑ILD)
- Nanoparticle formulation and prodrug design
- Preclinical modeling and in vivo imaging
Key Technologies
- Self‑assembling drug‑only nanoparticles
- Amphiphilic carrier nanoparticle design
- Pulmonary aerosol/inhalation formulations
- Mucus‑penetrating formulation technologies
News & Updates
A scientific publication by Fausto Chiazza, Elena Mantovani, Alessandro Marengo, Davide Russo, Beatrice Ragnoli, Mario Malerba presenting a new imaging approach for nanostructured mycophenolic acid in preclinical models.
A scientific publication by Fausto Chiazza, Elena Mantovani, Alessandro Marengo, Davide Russo, Beatrice Ragnoli, Mario Malerba presenting a new imaging approach for nanostructured mycophenolic acid in preclinical models.